Explore

Does dapagliflozin vs placebo affect OUT:cv-death-or-worsening-hf in Heart Failure with Reduced Ejection Fraction?

1 studies (4,744 patients, 1 RCTs) provide moderate-certainty evidence for benefit of dapagliflozin for Composite of worsening HF or cardiovascular death in Heart Failure with Reduced Ejection Fraction.

Does dabigatran vs warfarin improve outcomes in HEART-VALVE, MECHANICAL?

25 studies (732,515 patients) provide low-certainty evidence for benefit of dabigatran for Ventricular Arrhythmia in HEART-VALVE, MECHANICAL.

Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?

25 studies (460,637 patients) provide low-certainty evidence for benefit of immune checkpoint inhibitors for Cardiac Index in cancer therapy-related cardiovascular toxicity.

Does rivaroxaban vs apixaban improve outcomes in Venous Thromboembolism?

5 studies (48,024 patients) provide low-certainty evidence for benefit of rivaroxaban for Cardiac Output in Venous Thromboembolism.

Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in Acute Coronary Syndrome?

3 studies (41,464 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in Acute Coronary Syndrome.

Does inspiratory muscle training (imt) vs placebo improve Peak Oxygen Consumption in Heart Failure, Diastolic?

2 studies (1,483 patients) provide low-certainty evidence for benefit of inspiratory muscle training (imt) for Peak Oxygen Consumption in Heart Failure, Diastolic.

Does amiodarone vs placebo improve outcomes in Atrial Fibrillation?

10 studies (49,075 patients) provide low-certainty evidence against benefit of amiodarone for Myocardial Infarction Hospitalization in Atrial Fibrillation.

Does apixaban vs enoxaparin improve outcomes in Venous Thromboembolism?

6 studies (6,044 patients) provide low-certainty evidence against benefit of apixaban for Cardiac Output in Venous Thromboembolism.

Does asparaginase vs placebo improve outcomes in L2 Acute Lymphoblastic Leukemia?

4 studies (221 patients) provide low-certainty evidence against benefit of asparaginase for Myocardial Infarction Hospitalization in L2 Acute Lymphoblastic Leukemia.

Does phenylephrine vs placebo improve Systolic Blood Pressure?

2 studies (45 patients) provide low-certainty evidence against benefit of phenylephrine for Systolic Blood Pressure in this population.

Does dipyridamole vs placebo improve Left Ventricular Ejection Fraction in Aortic Valve Stenosis?

2 studies (30 patients) provide low-certainty evidence against benefit of dipyridamole for Left Ventricular Ejection Fraction in Aortic Valve Stenosis.